Prevention of pneumococcal disease in young children

Related Experiment Video

Updated: Oct 1, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

D Steimle1, R Aston, P Van Damme

  • 1European Vaccine Manufacturers, Brussels, Belgium. dianasteimle@efpia.org

Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|April 30, 2002
PubMed

Insights

Antimicrobial resistance necessitates vaccination. A new conjugate pneumococcal vaccine offers protection for young children, potentially reducing antibiotic use and hospitalizations.

Area of Science:

  • Microbiology
  • Immunology
  • Public Health

Background:

  • Increasing global pneumococcal resistance to antimicrobial drugs highlights the need for effective vaccines.
  • Traditional polysaccharide pneumococcal vaccines are limited in protecting children under two years old, a high-risk group.

Purpose of the Study:

  • To introduce a new conjugate pneumococcal vaccine designed to overcome the limitations of traditional vaccines.
  • To assess the potential impact of the new conjugate vaccine on antibiotic treatment, healthcare utilization, and hospitalization rates.

Main Methods:

  • The study focuses on the development and expected impact of a novel conjugate pneumococcal vaccine.
  • Analysis of projected outcomes based on vaccine efficacy and epidemiological data.

Main Results:

  • The new conjugate vaccine is anticipated to provide crucial protection for infants and young children.
  • Expected outcomes include a reduced reliance on antibiotic treatments for pneumococcal infections.

Conclusions:

  • The conjugate pneumococcal vaccine represents a significant advancement in combating pneumococcal disease, particularly in high-risk young populations.
  • This vaccine is projected to decrease the incidence of pneumococcal infections, leading to fewer general practitioner visits and hospital admissions.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...